Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

472 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol.
Morel P, Munck JN, Coiffier B, Gisselbrecht C, Ranta D, Bosly A, Tilly H, Quesnel B, Thyss A, Mounier N, Brière J, Molina T, Reyes F; Groupe d'Etude de Lymphomes des l'Adulte (GELA). Morel P, et al. Among authors: tilly h. Leuk Lymphoma. 2010 Sep;51(9):1668-77. doi: 10.3109/10428194.2010.504871. Leuk Lymphoma. 2010. PMID: 20807094 Clinical Trial.
Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma-Final Analysis.
Maerevoet M, Casasnovas O, Cartron G, Morschhauser F, Thieblemont C, Bouabdallah K, Feugier P, Szablewski V, Becker S, Tilly H. Maerevoet M, et al. Among authors: tilly h. Cancers (Basel). 2024 Jul 26;16(15):2672. doi: 10.3390/cancers16152672. Cancers (Basel). 2024. PMID: 39123400 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 39112148
[No title available]
[No authors listed] [No authors listed] PMID: 39112412
Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials.
Lenz G, Tilly H, Ziepert M, Altmann B, Herbaux C, Frontzek F, Nickelsen M, Lee C, Hirata J, Sahin D, Chohan S, Batlevi CL, Yan M, Morschhauser F, Schmitz N. Lenz G, et al. Among authors: tilly h. Leukemia. 2024 Sep 25. doi: 10.1038/s41375-024-02420-6. Online ahead of print. Leukemia. 2024. PMID: 39322715 No abstract available.
NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.
Cheminant M, Bruneau J, Malamut G, Sibon D, Guegan N, van Gils T, Cording S, Trinquand A, Verkarre V, Lhermitte L, Brousse N, Jannot AS, Khater S, Frenzel L, Delarue R, Suarez F, Marçais A, Mulder CJ, Macintyre E, Asnafi V, Pouyet L, Bonnafous C, Lhospice F, Molina TJ, Meresse B, Cellier C, Cerf-Bensussan N, Hermine O; CELAC network°. Cheminant M, et al. Gut. 2019 Aug;68(8):1396-1405. doi: 10.1136/gutjnl-2018-317371. Epub 2018 Nov 17. Gut. 2019. PMID: 30448772
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Stathis A, Pirosa MC, Orsucci L, Feugier P, Tani M, Ghesquières H, Musuraca G, Rossi FG, Merli F, Guièze R, Gyan E, Gini G, Marino D, Gressin R, Morschhauser F, Cavallo F, Palombi F, Conconi A, Tessoulin B, Tilly H, Zanni M, Cabras MG, Capochiani E, Califano C, Celli M, Pulsoni A, Angrilli F, Occhini U, Casasnovas RO, Cartron G, Devizzi L, Haioun C, Liberati AM, Houot R, Merli M, Pietrantuono G, Re F, Spina M, Landi F, Cavalli F, Bertoni F, Rossi D, Ielmini N, Borgo E, Luminari S, Zucca E, Thieblemont C. Stathis A, et al. Among authors: tilly h. Haematologica. 2024 Aug 1;109(8):2564-2573. doi: 10.3324/haematol.2023.283918. Haematologica. 2024. PMID: 38385243 Free PMC article. Clinical Trial.
Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5' RACE.
Camus V, Viennot M, Viailly PJ, Drieux F, Veresezan EL, Bobée V, Rainville V, Bohers E, Sesques P, Haioun C, Durot E, Bayaram M, Rossi C, Martin L, Penther D, Kaltenbach S, Bruneau J, Paillassa J, Tournilhac O, Gower N, Willaume A, Antier C, Renaud L, Leveque E, Decazes P, Becker S, Tonnelet D, Gaulard P, Tilly H, Molina T, Traverse-Glehen A, Donzel M, Ruminy P, Jardin F. Camus V, et al. Among authors: tilly h. Blood Adv. 2024 Sep 18:bloodadvances.2024013723. doi: 10.1182/bloodadvances.2024013723. Online ahead of print. Blood Adv. 2024. PMID: 39293080
MYC Rearrangement Prediction From LYSA Whole Slide Images in Large B-Cell Lymphoma: A Multicentric Validation of Self-supervised Deep Learning Models.
Syrykh C, Di Proietto V, Brion E, Copie-Bergman C, Jardin F, Dartigues P, Gaulard P, Molina TJ, Briere J, Oberic L, Haioun C, Tilly H, Maussion C, Morel M, Schiratti JB, Laurent C. Syrykh C, et al. Among authors: tilly h. Mod Pathol. 2024 Sep 10;37(12):100610. doi: 10.1016/j.modpat.2024.100610. Online ahead of print. Mod Pathol. 2024. PMID: 39265953
Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity.
Moreno-Arciniegas A, García A, Kelm M, D'Amore F, da Silva MG, Sánchez-González J, Sánchez PL, López-Fernández T, Córdoba R, Asteggiano R, Camus V, Smink J, Ferreira A, Kersten MJ, Bolaños N, Escalera N, Pacella E, Gómez-Talavera S, Quesada A, Rosselló X, Ibanez B; RESILIENCE Trial Investigators. Moreno-Arciniegas A, et al. Eur J Heart Fail. 2024 Aug 30. doi: 10.1002/ejhf.3395. Online ahead of print. Eur J Heart Fail. 2024. PMID: 39212445
472 results